Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00322517 · ClinicalTrials.gov registry record · Phase 2
Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer
A Phase 2 study of Breast Neoplasms, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT00322517: Completed Phase 2 study of Breast Neoplasms, sponsored by Pfizer.
NCT00322517 is a Phase 2 study of Breast Neoplasms that has completed, run by Pfizer. The registered enrollment target is 90 participants, below the 568-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00322517, a Phase 2 study of Breast Neoplasms, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
To determine the antitumor efficacy and the safety of SU-014813 at a dose of 100 mg orally once daily in patients with Metastatic Breast Cancer
Conditions Studied
Interventions
- DRUG SU014813
Study Locations (20)
Other
- Pfizer Investigational Site - Hamburg
- Pfizer Investigational Site - Magdeburg
- Pfizer Investigational Site - Marburg
- Pfizer Investigational Site - Chieti Scalo
- Pfizer Investigational Site - Milan
- Pfizer Investigational Site - Mirano (VE)
- Pfizer Investigational Site - Udine
- Pfizer Investigational Site - Amsterdam
- Pfizer Investigational Site - Rotterdam
- Pfizer Investigational Site - Edinburgh
California
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Pasadena
- Pfizer Investigational Site - Santa Monica
- Pfizer Investigational Site - Valancia
Mississippi
- Pfizer Investigational Site - Corinth
- Pfizer Investigational Site - Southaven
Tennessee
- Pfizer Investigational Site - Memphis
- Pfizer Investigational Site - Memphis
M20 4bx
- Pfizer Investigational Site - Manchester
Surrey
- Pfizer Investigational Site - Sutton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
What the finished NCT00322517 record still lists
NCT00322517 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 568-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which SU014813 is the first listed.
NCT00322517 names 20 study sites across 6 states, led by Other, California, Mississippi.
Frequently Asked Questions
What is clinical trial NCT00322517 about?
NCT00322517 is a clinical study titled "Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer". To determine the antitumor efficacy and the safety of SU-014813 at a dose of 100 mg orally once daily in patients with Metastatic Breast Cancer
What is the current status of trial NCT00322517?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2006-04. Estimated completion is 2009-07.
What conditions does trial NCT00322517 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT00322517?
The interventions under investigation include: SU014813 (DRUG).
Who is sponsoring clinical trial NCT00322517?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00322517 being conducted?
This trial has 20 study locations across California, Mississippi, Tennessee, M20 4bx, Surrey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00322517's enrollment target sits among peer trials
90 59th of 97 higher than 39 of 97 other Breast Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
-
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
RECRUITING · Phase 2
-
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
RECRUITING · Phase 2
-
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
RECRUITING · Phase 2
-
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia